3M Drug Delivery Systems - Blog Article

3M Drug Delivery Systems Blog

  • October is Breast Cancer Awareness Month

    • During the month of October, pink is a prominent color. It represents the fight against breast cancer, which is the second most common form of cancer in women. As we observe Breast Cancer Awareness Month, we are also faced with the grim reality that cancer in all forms is a growing threat to the health of men, women and children around the world.

      According to the World Health Organization, over the next two decades, the number of new cancer cases is expected to rise by about 70% to 22 million worldwide. While researchers continue to lead us closer to knowing the causes of various types of cancer and even potential cures, they also continue to improve treatment options for patients currently suffering from the disease.

      This year, 3M Drug Delivery Systems and Panacea Pharmaceuticals marked a major milestone in the development of an investigational therapeutic cancer vaccine. The first patient in a Phase 1 clinical study evaluating safety and immunogenicity in cancer patients has been dosed using the 3M™ Hollow Microstructured Transdermal System (hMTS).

      There are three main benefits for using this drug delivery method.

      1. Preclinical studies have shown a potentially better immune response with the hMTS when compared to intramuscular dosing. This is critical for the enhanced effectiveness of the cancer vaccine.
      2. The second benefit is the acceptability of the dosing that comes from the comfort of the patient during drug administration.
      3. Third is the market benefit of a cancer vaccine product that is matched with a unique, microneedle delivery device that insures consistent, easy delivery of the full vaccine dose.

       

      An additional benefit is the potential to reduce healthcare costs, due to improved patient outcomes. According to the World Health Organization, the economic impact of cancer is significant and on the rise. Globally, the total cost of cancer in 2010 was estimated at $1.16 trillion. Innovation like this drug and its delivery system is critical for keeping rising healthcare costs in check, as well as improving the lives of patients battling this devastating disease.